Search clinical trials for: GRC 54276 Pembrolizumab

Total 3426 results

Cancer Research UK

Unknown

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Lymphoma
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Finland, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Gua... and more
Joseph J. Cullen, MD, FACS
Holden Comprehensive Cancer Center

Not yet recruiting

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients (XACT-PANC-2)

Pancreatic Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
University of British Columbia

Unknown

Graceful Lifestyle Changes Study for PCOS and Infertility (GLC)

Polycystic Ovary Syndrome | Infertility
Bristol-Myers Squibb

Completed

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Rheumatoid Arthritis

Belgium, Spain, United States, Germany, Italy, Mexico, United Kingdom, France, Czech Republic, Ireland
M.D. Anderson Cancer Center

Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative Neoplasm

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
University of California, San Francisco
Merck Sharp & Dohme LLC

Withdrawn

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...

United States
Roswell Park Cancer Institute
AIM ImmunoTech Inc.

Completed

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple -Negative Breast Cancer | Anatomic Stage IV Breast Cancer AJCC

United States
Hoffmann-La Roche

Terminated

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)

Breast Cancer

United States, Brazil, Australia, Canada, Japan, Korea, Republic of, Spain, United Kingdom
University of Kansas Medical Center

Recruiting

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC (NeoTRACT)

Breast Cancer | Triple Negative Breast Cancer

United States
Stanford University
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Relapsed Classical Hodgkin Lymphoma

United States
Seoul National University Hospital

Active, not recruiting

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Pancreatic Cancer | Chemotherapy Effect

Korea, Republic of
Hackensack Meridian Health

Terminated

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Multiple Myeloma

United States
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
NYU Langone Health
Celgene

Terminated

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Multiple Myeloma

United States
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal

Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Lymphocyte-Rich Classical Hodgkin Lymphoma | Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Recurrent Mixed Cellularity Classical Hodgkin Lymphoma | Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma | Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma | Refractory Mixed... and other conditions

United States
University of Alabama at Birmingham
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)

Parkinson Disease

United States
University of Sao Paulo

Completed

Primary Molars Restorations With Encapsulated or Hand-Mixed Glass Ionomer: Clinical Trial

Dental Caries

Brazil
Takeda

Completed

A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.

Uterine Fibroids
Brian Jonas
National Cancer Institute (NCI); AbbVie

Recruiting

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia

United States
Global Coalition for Adaptive Research
Bayer; Kazia Therapeutics Limited; Biohaven Pharmaceuticals, Inc.; Kintara Therapeutics... and other collaborators

Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Glioblastoma

United States, France, Germany, Canada, Australia, Switzerland
Hoffmann-La Roche

Active, not recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, Australia, Spain, France
Medical College of Wisconsin

Terminated

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE)

Acute Myelogenous Leukemia

United States
AbbVie
Roche-Genentech

Active, not recruiting

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Multiple Myeloma

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Russian Federation, Singapore, Spain, Sweden, Turkey, Ukraine, United Kingdom
M.D. Anderson Cancer Center

Active, not recruiting

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia

United States
AbbVie
Celgene

Terminated

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

Metastatic Malignant Female Reproductive System Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Omar Younis
Ain Shams University

Completed

Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients (DACAMI)

Anterior MI

Egypt
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Peking Union Medical College Hospital
Peking University People's Hospital; Chinese PLA General Hospital; Tongji Hospital and other collaborators

Recruiting

Withdraw Drug in Stable IgG4-Related Disease

Autoimmune Diseases

China
Marmara University

Completed

The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.

Breast Cancer

Turkey
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

First-line Treatment | HER2-positive Metastatic Breast Cancer

China
Oncotherapeutics
Karyopharm Therapeutics Inc

Recruiting

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Refractory Multiple Myeloma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Incyte Corporation

Active, not recruiting

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Metastatic Pancreatic Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Non-Small Cell Lung Carcinoma
Centre Hospitalier Universitaire Vaudois
Unisanté Centre universitaire de médecine générale et santé publique; FORCE...

Not yet recruiting

Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance (DAR-ARC)

Febrile Neutropenia

Switzerland
Cairo University

Not yet recruiting

Clinical and Radiographic Evaluation of Zirconomer Restorative (Zirconomer)

Dental Caries in Children | Dental Materials

Search clinical trials for: GRC 54276 Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations